Pediatric and young adult (

Abstract

21003 Background: Evaluate treatment results of the pediatric and young adult (< 21 year of age) patients with non-metastatic nasopharyngeal carcinoma (NPC) who were treated with neoadjuvant cisplatin + docetaxel (CD) and radiotherapy. Patients and Methods: Ten patients with NPC diagnosed between 2004–2007 have been treated with four cycles of CDDP 100 mgr/m2 + docetaxel 75 mg/m2 on day 1 with premedication every three weeks. Radiotherapy doses were 60 Gy to the primary tumor and positive lymph node regions and 40 Gy supraclavicular field by shielding the clavicules. Five children was monitored with serum EBV DNA quantification at diagnosis, after each cycle of chemotherapy, before radiotherapy and at follow-up. Results: Median age of the patients was 14 (9–20) with a male/female ratio of 6/4. Stage distribution was as follows: 2 with stage IIb, 2 with stage III, 4 pts with stage IVa, and 2 with stage IVb. One patient had a near complete response, 5 had partial response, and 3 had stable disease after CD chemotherapy and 1 progressed during CD chemotherapy. Over all survival rate in our protocol was 90%, whereas event free survival rate was 80%. No major chemotherapy toxicity was observed. EBV DNA titers were higher levels in two out of five patients at the time of diagnosis. Conclusion: Cisplatin+docetaxel combination was safe and effective in childhood nasopharyngeal carcinoma. There were no major toxicity during the chemotherapy. Plasma EBV DNA is useful for monitoring patients with nasopharyngeal carcinoma and predicting the outcome of treatment. No significant financial relationships to disclose.